Serum Metabolomic Characteristics of Patients with Liver Cirrhotic Ascites

Yang, Tao; Zheng, Xuan; Feng, Xing; Zhuo, Hua; Liu, Chenghai

doi:10.1159/000370242

Cited by 7 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decrease in proline level in patients' sera can be explained by the high consumption of proline in more collagen biosynthesis in liver cirrhosis. Results in HCC by Chan W (41) and evaluations of patients with liver cirrhotic ascites by Yang T showed decreased in proline (42). Our study showed that the levels of VLDL were reduced in the decompensated LC group compared to healthy controls.…”

Section: Cytosolic Pathwaysupporting

confidence: 49%

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

et al. 2017

View full text Add to dashboard Cite

Background: Cirrhosis is recognized by a reduction in hepatocyte proliferation with an increase in fibrous tissue, which may ultimately lead to the development of cancerous nodules. Liver biopsy has remained the gold standard for confirming liver fibrosis stages, but there are not any nonreversible and specific therapeutic targets in advanced cirrhosis. In the present study, we used the NMR method to find potential therapeutic markers in serum of HCV -cirrhotic patients with advanced stage.Methods: A metabolic profiling study was conducted using 2 groups: decompensated HCV-cirrhosis patients (n = 21) and healthy controls (n = 18). 1H nuclear magnetic resonance (NMR) approach was used to obtain the serum metabolic profiles of the samples. The acquired data were processed by the multivariate principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). Moreover, metabolic pathways were determined using MetaboAnalyst 3.0.Results: Specifically, 16 metabolites showed alteration between the 2 groups. Compared with healthy controls, a number of metabolites showed increased concentration in serum of decompensated HCV-cirrhosis such as succinic acid, isovaleraldehyde, citrulline, propanal and cinnamaldehyde, while several others were observed in decreased levels in the decompensated HCV-cirrhosis such as valine, glutamine, trimethylamine, lactate, proline, aspartate, lipid, VLDL, isoleucine, fucose, and glutamate. Aminoacyl-tRNA biosynthesis, alanine, aspartate, glutamate metabolism and arginine, and proline metabolism are the most significant pathways associated with advanced HCV-cirrhosis. Conclusions:Metabolomic profiling through NMR can identify the metabolic disturbances in advanced HCV-cirrhosis. Aberrant amino acid biosynthesis may be the hallmark with increasing severity of cirrhosis as well as alterations in energetic metabolism.

show abstract

Section: Cytosolic Pathwaysupporting

confidence: 49%

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Other studies showed that greater concentration of lysoPC in hepatic tissue are observed in non-alcohol steatohepatitis patients compared to healthy controls (Puri et al, 2007; Han et al, 2008). Finally, Yang et al (2014) showed that lysoPCs were identified as a potential biomarker for early diagnosis of liver fibrosis and cirrhosis. In the current study, the levels of lysoPCs (16:0, 18:2, and 22:6) were detected to be significantly higher in the LC group compared to the control group at baseline.…”

Section: Discussionmentioning

confidence: 99%

Liver Cirrhosis Patients Who Had Normal Liver Function Before Liver Cirrhosis Development Have the Altered Metabolic Profiles Before the Disease Occurrence Compared to Healthy Controls

Yoo

Kim

et al. 2019

Front. Physiol.

View full text Add to dashboard Cite

Liver cirrhosis (LC) is the final usual outcome of liver damage induced by various chronic liver diseases. Because of asymptomatic nature of LC, it is usually diagnosed at late and advanced stages, and patients are easy to miss the best timing for treatment. Thus, the early detection of LC is needed. In the prospective Korean Cancer Prevention Study-II (K-II), we aimed to identify valuable biomarkers for LC using metabolomics to distinguish subjects with incident LC (LC group) from subjects free from LC (control group) during a mean 7-year follow-up period. Metabolic alterations were investigated using baseline serum specimens acquired from 94 subjects with incident LC and 180 age- and sex-matched LC-free subjects via ultra-performance liquid chromatography (UPLC)-linear-trap quardrupole (LTQ)-Orbitrap mass spectrometry (MS). As a result of the metabolic analysis, 46 metabolites were identified. Among them, 11 and 18 metabolite level showed a significant increase and decrease, respectively, in the LC group compared to the control group. Nine metabolic pathways, including glyoxylate and dicarboxylate metabolism, amino acid metabolism, fatty acid metabolism, linoleic acid metabolism, α-linolenic acid metabolism, and arachidonic acid metabolism, were significantly different between the two groups. Logistic regression demonstrated that the LC emergence was independently affected by serum levels of myristic acid, palmitic acid, linoleic acid, eicosapentaenoic acid (EPA), lysophosphatidic acid (LPA) (18:1), glycolic acid, lysophosphatidylcholine (lysoPC) (22:6), and succinylacetone (R2 = 0.837, P < 0.001). This prospective study revealed that dysregulation of various metabolism had the clinical relevance on the LC development. Moreover, myristic acid, palmitic acid, linoleic acid, EPA, LPA (18:1), glycolic acid, lysoPC (22:6), and succinylacetone were emerged as independent variables influencing the incidence of LC. The results support that the early biomarkers found in this study may useful for predicting and remedying the risk of LC.

show abstract

“…In this view, the present work aimed to apply GC-MS based urine metabolomics of LC and HCC patients using untargeted analysis for novel biomarkers identification and to explore metabolites changes in these patients compared with healthy subjects. Yuan, Wang, Zhao, & Chen, 2013;Yang, Zheng, Xing, Zhuo, & Liu, 2014).…”

Section: Data Processing and Statistical Analysismentioning

confidence: 99%

“…PCA model (a) and ROC curve (b) for differentiation between LC and control groups Yuan,Wang, Zhao, & Chen, 2013;Yang, Zheng, Xing, Zhuo, & Liu, 2014).…”

mentioning

confidence: 99%

Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients

Osman

Ali

Obada

et al. 2016

Biomedical Chromatography

View full text Add to dashboard Cite

Metabolomics has been shown to be an effective tool for disease diagnosis, biomarker screening and characterization of biological pathways. A total of 140 subjects were included in this study; urine metabolomes of patients with liver cirrhosis (LC, n = 40), patients with hepatocellular carcinoma (HCC; n = 55) and healthy male subjects (n = 45) as a control group were studied. Gas chromatography/mass spectrometry-based urine metabolomics profiles were investigated for all participants. Diagnostic models were constructed with a combination of marker metabolites, using principal components analysis and receiver operator characteristic curves. A total of 57 peaks could be auto-identified of which 13 marker metabolites (glycine, serine, threonine, proline, urea, phosphate, pyrimidine, arabinose, xylitol, hippuric acid, citric acid, xylonic acid and glycerol) were responsible for the separation of HCC group from healthy subjects. Also, eight markers metabolites (glycine, serine, threonine, proline, citric acid, urea, xylitol and arabinose) showed significant differences between the LC group and healthy subjects. No significant difference was detected between HCC and LC groups regarding all these metabolites. Metabolomic profile using GC-MS established an optimized diagnostic model to discriminate between HCC patients and healthy subjects; also it could be useful for diagnosis of LC patients. However, it failed to differentiate between HCC and LC patients.

show abstract

Serum Metabolomic Characteristics of Patients with Liver Cirrhotic Ascites

Cited by 7 publications

References 13 publications

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

Liver Cirrhosis Patients Who Had Normal Liver Function Before Liver Cirrhosis Development Have the Altered Metabolic Profiles Before the Disease Occurrence Compared to Healthy Controls

Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients

Contact Info

Product

Resources

About